Spectral AI raises $7.6 Million of Additional Growth Capital
Spectral AI (Nasdaq: MDAI) priced a $7.6 million offering on October 23, 2025 to fund expansion of its DeepView® System. The financing includes the issuance of 4,000,000 shares of common stock and pre-funded warrants at $1.90 per share, plus corresponding warrants with an exercise price of $2.51 per share.
The company said proceeds will support continued development, broaden clinical indications, and prepare for commercial readiness in 2026, while maintaining support for its BARDA Project BioShield contract. Northland Capital Markets served as exclusive placement agent and Reed Smith served as counsel.
Spectral AI (Nasdaq: MDAI) ha delineato un’offerta da $7.6 million il 23 ottobre 2025 per finanziare l’espansione del suo sistema DeepView®. La finanziamento include l’emissione di 4,000,000 azioni ordinarie e warrant prefinanziati a $1.90 per azione, più warrant corrispondenti con un prezzo di esercizio di $2.51 per azione.
L’azienda ha dichiarato che i proventi supporteranno lo sviluppo continuo, l’ampliamento delle indicazioni cliniche e la preparazione per la prontezza commerciale nel 2026, mantenendo al contempo il supporto al suo contratto BARDA Project BioShield. Northland Capital Markets ha operato come agente di collocamento esclusivo e Reed Smith come consulente legale.
Spectral AI (Nasdaq: MDAI) fijó una oferta de $7.6 millones el 23 de octubre de 2025 para financiar la expansión de su sistema DeepView®. La financiación incluye la emisión de 4,000,000 de acciones ordinarias y warrants prefinanciados a $1.90 por acción, más warrants correspondientes con un precio de ejercicio de $2.51 por acción.
La empresa dijo que los ingresos respaldarán el desarrollo continuo, ampliarán las indicaciones clínicas y se prepararán para la disponibilidad comercial en 2026, manteniendo el apoyo a su contrato BARDA Project BioShield. Northland Capital Markets actuó como agente de colocación exclusivo y Reed Smith como asesor.
Spectral AI (나스닥: MDAI)가 DeepView® 시스템 확장을 위해 2025년 10월 23일 $7.6백만 규모의 공모를 가격 결정했습니다. 이번 자금조달에는 4,000,000주의 보통주와 주당 $1.90의 선매권이 발행되며, 행사 가격이 주당 $2.51인 해당 권리도 함께 발행됩니다.
회사는 조달금이 지속적인 개발을 지원하고 임상 적응 범위를 확대하며 2026년 상용 준비를 준비하는 데 사용될 것이며, BARDA Project BioShield 계약에 대한 지원도 유지할 것이라고 밝혔습니다. Northland Capital Markets가 독점 배정 대리점으로, Reed Smith가 고문으로 활동했습니다.
Spectral AI (Nasdaq: MDAI) a fixé une offre de $7.6 millions au 23 octobre 2025 pour financer l’expansion de son système DeepView®. Le financement comprend l’émission de 4,000,000 actions ordinaires et des warrants préfinancés à $1.90 par action, plus des warrants correspondants avec un prix d’exercice de $2.51 par action.
La société indique que les produits seront destinés au développement continu, à élargir les indications cliniques et à se préparer à une mise sur le marché en 2026, tout en maintenant le soutien à son contrat BARDA Project BioShield. Northland Capital Markets a agi en tant qu’agent de placement exclusif et Reed Smith a agi en tant que conseil.
Spectral AI (Nasdaq: MDAI) hat am 23. Oktober 2025 eine Angebot über $7.6 Millionen platziert, um die Expansion seines DeepView®-Systems zu finanzieren. Die Finanzierung umfasst die Emission von 4,000,000 Stammaktien und vorausbezahlten Warrants zu $1.90 pro Aktie, sowie entsprechende Warrants mit einem Ausübungspreis von $2.51 pro Aktie.
Das Unternehmen gab an, dass die Erlöse die fortgesetzte Entwicklung unterstützen, klinische Indikationen erweitern und die Marktreife im Jahr 2026 vorbereiten sollen, während gleichzeitig die Unterstützung für seinen BARDA Project BioShield-Vertrag aufrechterhalten wird. Northland Capital Markets fungierte als exklusiver Platzierungsvertreter und Reed Smith als Rechtsberatung.
Spectral AI (ناسداك: MDAI) حددت عرضاً بقيمة $7.6 مليون في 23 أكتوبر 2025 لتمويل توسيع نظام DeepView®. يتضمن التمويل إصدار 4,000,000 من الأسهم العادية وشيكات مسبقة التمويل بسعر $1.90 للسهم، بالإضافة إلى أسهم حق الحصول على أسهم مع سعر ممارس قدره $2.51 للسهم.
وقالت الشركة إن العائدات ستدعم التطوير المستمر، وتوسيع المؤشرات السريرية، والاستعداد لتوافر تجاري في 2026، مع الحفاظ على الدعم لعقد BARDA Project BioShield الخاص بها. عملت Northland Capital Markets كوكيل طرح حصري وReed Smith كمستشار قانوني.
Spectral AI（纳斯达克：MDAI） 于2025年10月23日定价一项 $7.6 百万美元 的发行，用于扩展其 DeepView® 系统。此次融资包括发行 4,000,000 股普通股和每股 $1.90 的预先融资认股权证，以及行使价为每股 $2.51 的相应认股权证。
公司表示，募集资金将用于持续开发、拓展临床适应症，并为在 2026 年实现商业就绪 做准备，同时维持对其 BARDA Project BioShield 合同的支持。Northland Capital Markets 担任独家配售代理，Reed Smith 担任律师事务所。
- Raised $7.6M of additional growth capital
- Issued 4,000,000 shares and pre-funded warrants
- Offering priced at $1.90 per share
- Warrants have $2.51 exercise price
- Proceeds allocated to DeepView System development and 2026 commercial readiness
- Placement agent: Northland Capital Markets
- Potential shareholder dilution from issuance of 4,000,000 new shares
- No detailed breakdown of use of proceeds or runway disclosed
DALLAS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the pricing of a
The transaction includes the issuance of 4,000,000 shares of its common stock and pre-funded warrants at a price of
J. Michael DiMaio, MD, Chairman of the Board of Spectral AI, said, “I am pleased that we were able to secure institutional funding for Spectral AI. This financing ensures that we can continue to develop and expand the DeepView System’s clinical indications and prepare for commercial readiness in 2026. We remain fully committed to supporting our current BARDA Project BioShield (PBS) contract, while also advancing our AI-powered technology to broaden our product offerings and deliver innovative solutions to the global medical community.”
Northland Capital Markets acted as the exclusive placement agent for the Company.
Reed Smith, LLP acted as counsel to the Company.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
How much did Spectral AI (MDAI) raise in the October 23, 2025 offering?
How many shares and what price were included in Spectral AI's (MDAI) offering?
What are the warrant terms in Spectral AI's (MDAI) financing?
What will Spectral AI (MDAI) use the $7.6M for?
Did Spectral AI (MDAI) name advisors for the offering?
